NASDAQ:XFOR   X4 Pharmaceuticals, Inc
- Triangle breakout
- buy pullbacks dips
- Tipranks Analyst rating $22 median price target
- The FDA has designated Rare Pediatric Disease status to X4 Pharmaceuticals ( XFOR -2.4%) for its lead asset, mavorixafor, for the treatment of WHIM (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis), a rare inherited, immunodeficiency disease caused by genetic mutations in the CXCR4 receptor gene (Vandana Singh, SA)

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.